Walleye Trading’s Aimmune Therapeutics AIMT Stock Holding History

Walleye Trading’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,240	Closed	-$123K	–	4803
2020 Q1	$104K	Buy	+7,240	New	+$185K	﹤0.01%	3090

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Trading's AIMT Position: Q2 2020 in Review

Walleye Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 7,240 shares — an estimated $123K sold.

Walleye Trading first reported a position in AIMT in Q1 2020 and held it in 1 quarter. The position peaked at $104K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Walleye Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Walleye Trading sold 7,240 Aimmune Therapeutics shares in Q2 2020, an estimated $123K.
Walleye Trading first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 1 quarter.
Walleye Trading's Aimmune Therapeutics position peaked at $104K in Q1 2020.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Walleye Trading's 13F filing for Q2 2020, filed 14 Aug 2020.